Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Iovance Biotherapeutics

Main focus: Tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer

Company stage: Clinical

Diseases (gene editing): Cancer

Genome editing tool: TALEN

Funding stage: Public (NASDAQ:IOVA)

Location: San Carlos, CA, USA



Gene-editing partnerships: Cellectis

Iovance Biotherapeutics is a clinical stage company focusing on the development of cellular therapies. The company develops tumour infiltrating lymphocyte (TIL)-based therapies to treat various types of solid tumours. The company's engagemen in the gene-editing space comes through its collaboration with Cellectis, from which it has licenced the TALEN technology to develop PD-1 inactivated TILs.


HashtagIovance Biotherapeutics

Company: Iovance Biotherapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine